Navigation Links
PharmaNet Collaborates With the Cancer Immunotherapy Trials Network

PRINCETON, N.J., June 1, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that it is collaborating with the Cancer Immunotherapy Trials Network (CITN), a premier network of clinical investigators, institutions and thought leaders in the area of cancer immunotherapy and vaccines, in order to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.

"We are thrilled to collaborate with the Cancer Immunotherapy Trials Network multi-investigator team," commented Anthony Maida, PhD, MA, MBA, Vice President, Clinical Research and General Manager, Oncology. "The association allows us to identify oncology centers of excellence and thought leaders to collaborate on the development of cutting-edge therapeutics."

PharmaNet has been conducting clinical studies for innovative oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments.  The Company has extensive experience in the development of cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types. Two hundred local, regional and global oncology clinical trials have been awarded to PharmaNet in the past five years, including eleven registration programs, seven which resulted in NDA/MAA approvals.

PharmaNet's focus on the development of immunotherapies and cancer vaccines is based on a core team of immunotherapy experts and partnerships to support this initiative.

"Clinical development of immunotherapies and cancer vaccines requires a special understanding of the mechanism of action and a different approach than traditional cancer therapies," Dr. Maida added.  "We are working with clients to address the unique methodologies needed to evaluate efficacy and safety of this class of innovative therapeutics."

About PharmaNetPharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit

About Cancer Immunotherapy Trials Network (CITN)The CITN is a multi-investigator team formed to bring new immunotherapy agents to the clinic, with an emphasis on clinical trials of "high priority" agents that were identified at the 2007 National Cancer Institute (NCI) immunotherapy agent workshop and on clinical trials using combination products. In 2010, the CITN was funded by the National Institute for Health through a $14 million grant to the Fred Hutchinson Cancer Research Center where Dr. Martin 'Mac' Cheever is a principle investigator. For more information, please visit

Anne-Marie HessPhone:

(609) 951-6842E-mail:

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009
2. Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance
3. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
4. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
5. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
6. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
7. PharmaNet Development Group Announces Observational Research Survey
8. PharmaNet Launches New Brand Identity at Upcoming Industry Conferences
9. PharmaNets Technology Investments Translate to Enhanced Client Service in Its Phase I Clinics
10. Catherine Derasp Joins PharmaNet as Vice President, Clinical Operations
11. PharmaNet and Anapharm Europe Formally End Joint Venture
Post Your Comments:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):